'Special K' Once Again Wows Investigators in Small Depression Study
Yet another research team has pulled off a small study demonstrating the enormous potential of ketamine as a treatment for depression, highlighting again how difficult it has been to push beyond evidence of a rapid-acting treatment to develop a therapy with durable effects. Investigators at the Icahn School of Medicine at Mount Sinai say that they developed a low-dose, intranasal formulation of the drug that spurred a clear response among a small group of patients suffering from treatment responsive major depression disorder. "One of the primary effects of ketamine in the brain is to block the NMDA [N-methyl-d-aspartate] glutamate receptor," said James W. Murrough, MD, principal investigator of the study, and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.
-Dr. James W. Murrough, Associate Professor of Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai
Mount Sinai Researchers Identify Brain “Entrapment” Patterns Associated With Depression
Jun 11, 2026 View All Press Releases
